News

Roche launches new exome and custom KAPA Target Enrichment portfolio for translational and clinical research applications in sequencing

Roche launches new exome and custom KAPA Target Enrichment portfolio for translational and clinical research applications in sequencing

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of the new KAPA Target Enrichment portfolio, consisting of both exome and custom target enrichment solutions for sequencing. KAPA HyperExome is a whole exome research panel with significantly improved performance over the existing on-market SeqCap portfolio and other products on the market. In addition to the Target Enrichment portfolio, Roche is also launching the new HyperDesign tool that enables researchers to create custom target enrichment designs that utilize the new KAPA HyperChoice probes. The probes are paired with a streamlined, automatable workflow.

Every step of the next-generation sequencing sample prep process has the potential to impact results. KAPA Target Enrichment portfolio provides the high level of performance and consistency that is needed to empower clinical researchers to process more samples successfully while optimizing sequencing efficiency. These new target enrichment products, along with the KAPA library prep portfolio, provide researchers with a streamlined and fully automatable sample preparation workflow which decreases hands-on and turnaround time.

“Next-generation sequencing samples are precious, as samples often can only be collected once,” said Neil Gunn, Head of Roche Sequencing Solutions. “We are pleased to bring an upgraded target enrichment solution to our customers that will increase sequencing efficiency and provide researchers greater confidence in their results. This helps pave the way for the future of personalized healthcare for patients.”